NASDAQ:BLRX - Nasdaq - US09071M2052 - ADR - Currency: USD
3.4
+0.18 (+5.59%)
The current stock price of BLRX is 3.4 USD. In the past month the price increased by 8.78%. In the past year, price decreased by -88.16%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.69 | 339.48B | ||
AMGN | AMGEN INC | 14.57 | 155.24B | ||
GILD | GILEAD SCIENCES INC | 13.55 | 130.78B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1744.33 | 130.05B | ||
REGN | REGENERON PHARMACEUTICALS | 13.25 | 64.19B | ||
ARGX | ARGENX SE - ADR | 340.42 | 39.49B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 33.99B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.99B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.06B | ||
NTRA | NATERA INC | N/A | 20.37B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.70B | ||
BIIB | BIOGEN INC | 7.28 | 17.56B |
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.
BIOLINERX LTD-SPONS ADR
Modi'in Technology Park, 2 HaMa'ayan Street
Modiin 7177871 IL
CEO: Philip A. Serlin
Employees: 28
Company Website: https://www.biolinerx.com/
Investor Relations: http://ir.biolinerx.com/phoenix.zhtml?c=208785&p=irol-IRHome
Phone: 97286429100
The current stock price of BLRX is 3.4 USD. The price increased by 5.59% in the last trading session.
The exchange symbol of BIOLINERX LTD-SPONS ADR is BLRX and it is listed on the Nasdaq exchange.
BLRX stock is listed on the Nasdaq exchange.
BIOLINERX LTD-SPONS ADR (BLRX) has a market capitalization of 12.65M USD. This makes BLRX a Nano Cap stock.
BIOLINERX LTD-SPONS ADR (BLRX) currently has 28 employees.
BIOLINERX LTD-SPONS ADR (BLRX) has a resistance level at 3.23. Check the full technical report for a detailed analysis of BLRX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BLRX does not pay a dividend.
BIOLINERX LTD-SPONS ADR (BLRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.64).
The outstanding short interest for BIOLINERX LTD-SPONS ADR (BLRX) is 6.05% of its float. Check the ownership tab for more information on the BLRX short interest.
ChartMill assigns a technical rating of 2 / 10 to BLRX. When comparing the yearly performance of all stocks, BLRX is a bad performer in the overall market: 93.03% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to BLRX. Both the profitability and financial health of BLRX have multiple concerns.
Over the last trailing twelve months BLRX reported a non-GAAP Earnings per Share(EPS) of -2.64. The EPS increased by 88.19% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -23.7% | ||
ROE | -68.5% | ||
Debt/Equity | 0.75 |
ChartMill assigns a Buy % Consensus number of 100% to BLRX. The Buy consensus is the average rating of analysts ratings from 2 analysts.